[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69527429D1 - Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon - Google Patents

Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon

Info

Publication number
DE69527429D1
DE69527429D1 DE69527429T DE69527429T DE69527429D1 DE 69527429 D1 DE69527429 D1 DE 69527429D1 DE 69527429 T DE69527429 T DE 69527429T DE 69527429 T DE69527429 T DE 69527429T DE 69527429 D1 DE69527429 D1 DE 69527429D1
Authority
DE
Germany
Prior art keywords
derivatives
pseudomorphe
polymerphe
piperin
antihistaminic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69527429T
Other languages
English (en)
Other versions
DE69527429T2 (de
Inventor
R Henton
J Mccarty
I Tripp
E Dewitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69527429(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69527429D1 publication Critical patent/DE69527429D1/de
Publication of DE69527429T2 publication Critical patent/DE69527429T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
DE69527429T 1994-05-18 1995-04-28 Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon Expired - Lifetime DE69527429T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
PCT/US1995/004942 WO1995031437A1 (en) 1994-05-18 1995-04-28 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Publications (2)

Publication Number Publication Date
DE69527429D1 true DE69527429D1 (de) 2002-08-22
DE69527429T2 DE69527429T2 (de) 2003-03-20

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69527429T Expired - Lifetime DE69527429T2 (de) 1994-05-18 1995-04-28 Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon

Country Status (18)

Country Link
US (12) US20010014741A1 (de)
EP (3) EP0766668B1 (de)
JP (7) JPH10500134A (de)
CN (3) CN1623985A (de)
AT (1) ATE220667T1 (de)
AU (1) AU693892B2 (de)
CA (3) CA2189007C (de)
DE (1) DE69527429T2 (de)
DK (1) DK0766668T3 (de)
ES (1) ES2176329T3 (de)
FI (1) FI964565A0 (de)
HK (2) HK1098467A1 (de)
HU (1) HU227676B1 (de)
IL (3) IL134917A (de)
MX (1) MX9605613A (de)
NO (1) NO315319B1 (de)
PT (1) PT766668E (de)
WO (1) WO1995031437A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
JPH10500134A (ja) 1994-05-18 1998-01-06 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗ヒスタミン性ピペリジン誘導体の無水および水和形態、それらの多形態および擬似形態の製造方法
EP0812195B1 (de) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
IN191492B (de) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
MXPA03011728A (es) * 2001-06-18 2004-07-08 Reddyaes Lab Ltd Formas cristalinas novedosas del acido 4-[4-[4- (hidroxidifenilmetil) -1-piperidinil] -1-hidroxibutil] -alfa, alfa -dimetilbencen acetico y su clorohidrato.
US7700779B2 (en) 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
PT1414453E (pt) * 2001-07-31 2008-05-29 Texcontor Ets Polimorfo de cloridrato de fexofenadina
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
DE03757471T1 (de) * 2002-06-10 2005-09-01 Teva Pharmaceutical Industries Ltd. Polymorphe form xvi von fexofenadin-hydrochlorid
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
WO2005005447A2 (en) * 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (de) * 2004-06-15 2006-02-08 Dipharma S.p.A. Verfahren zur Herstellung von Keto-Verbindungen
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
EP2105134A1 (de) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stabiles und amorphes Fexofenadin-Hydrochlorid
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
KR20120115492A (ko) 2009-11-06 2012-10-18 바스프 에스이 ４―히드록시 벤조산 및 선택된 살충제의 결정질 복합체
IT1400965B1 (it) 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
WO2011158262A1 (en) 2010-06-15 2011-12-22 Chemelectiva S.R.L. Polymorphic form of fexofenadine hydrochloride, intermediates and process for its preparation
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (de) 1991-04-08 1993-01-11 Green Cross Corp
US5631375A (en) 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
WO1993021156A1 (en) * 1992-04-10 1993-10-28 Merrell Dow Pharmaceuticals Inc. 4-diphenylmethyl piperidine derivatives and process for their preparation
WO1993023047A1 (en) 1992-05-11 1993-11-25 Merrell Dow Pharmaceuticals Inc. Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
RU2167657C2 (ru) 1992-08-03 2001-05-27 Сепракор, Инк. Фармацевтическая композиция для лечения аллергических заболеваний, способ антигистаминного лечения, применение композиции для получения лекарственного препарата
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
EP0723958A1 (de) 1993-06-24 1996-07-31 Albany Molecular Research, Inc. Synthese von praktisch reinen Terfenadinderivaten
CA2181089C (en) 1993-06-24 2000-05-23 Thomas E. D'ambra Piperidine derivatives and process for their production
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
AU699559B2 (en) 1993-06-25 1998-12-10 Aventisub Ii Inc. Novel intermediates for the preparation of antihistaminic piperidine derivatives
JPH10500134A (ja) * 1994-05-18 1998-01-06 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗ヒスタミン性ピペリジン誘導体の無水および水和形態、それらの多形態および擬似形態の製造方法
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134770A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
EP0812195B1 (de) 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
US5574045A (en) 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
ID22891A (id) * 1997-08-26 1999-12-16 Hoechst Marion Roussel Inc Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
FI964565A (fi) 1996-11-14
JP2002316978A (ja) 2002-10-31
JP4503909B2 (ja) 2010-07-14
CA2449419C (en) 2011-09-06
US20070021462A1 (en) 2007-01-25
CA2585705C (en) 2012-04-17
ATE220667T1 (de) 2002-08-15
HK1098467A1 (en) 2007-07-20
CN1623985A (zh) 2005-06-08
CN1907967A (zh) 2007-02-07
DK0766668T3 (da) 2002-10-28
CA2189007A1 (en) 1995-11-23
HU227676B1 (en) 2011-11-28
US7138524B2 (en) 2006-11-21
AU2426595A (en) 1995-12-05
CN1907967B (zh) 2012-07-04
HUT76134A (en) 1997-06-30
US20010012896A1 (en) 2001-08-09
HK1137742A1 (en) 2010-08-06
CA2585705A1 (en) 1995-11-23
US20040014976A1 (en) 2004-01-22
PT766668E (pt) 2002-11-29
EP0766668B1 (de) 2002-07-17
CA2189007C (en) 2004-03-02
CA2449419A1 (en) 1995-11-23
US20030045721A1 (en) 2003-03-06
FI964565A0 (fi) 1996-11-14
CN1148849A (zh) 1997-04-30
NO964859L (no) 1996-11-15
IL134917A (en) 2001-07-24
JP2002255935A (ja) 2002-09-11
US20070021461A1 (en) 2007-01-25
US20080167471A1 (en) 2008-07-10
JP2010120969A (ja) 2010-06-03
MX9605613A (es) 1998-05-31
DE69527429T2 (de) 2003-03-20
EP1178041A1 (de) 2002-02-06
IL113747A (en) 2001-05-20
EP0766668A1 (de) 1997-04-09
JPH10500134A (ja) 1998-01-06
US20020193603A1 (en) 2002-12-19
HU9603167D0 (en) 1997-01-28
IL134917A0 (en) 2001-05-20
AU693892B2 (en) 1998-07-09
EP2354125A1 (de) 2011-08-10
JP2002308849A (ja) 2002-10-23
US20080167469A1 (en) 2008-07-10
IL113747A0 (en) 1995-08-31
US20010014741A1 (en) 2001-08-16
JP2002255936A (ja) 2002-09-11
US7662835B2 (en) 2010-02-16
US20020193600A1 (en) 2002-12-19
US20020193601A1 (en) 2002-12-19
ES2176329T3 (es) 2002-12-01
US7135571B2 (en) 2006-11-14
NO964859D0 (no) 1996-11-15
NO315319B1 (no) 2003-08-18
US7666881B2 (en) 2010-02-23
US20010025106A1 (en) 2001-09-27
JP4503908B2 (ja) 2010-07-14
WO1995031437A1 (en) 1995-11-23
JP4503907B2 (ja) 2010-07-14
JP2002308850A (ja) 2002-10-23

Similar Documents

Publication Publication Date Title
DE69527429D1 (de) Verfahren zur herstellung von wasserfreien und hydrat-formen von antihistaminischen piperinderivaten, polymerphe und pseudomorphe davon
DE68916699D1 (de) Benzopyridopiperidin, -piperidyliden und -piperazin-Verbindungen, Zusammensetzungen, Methoden zur Herstellung und Verwendung.
DE69116781D1 (de) Integriertes Verfahren zur Herstellung von Kohlenoxyd
FI874570A0 (fi) Antibakteriska medel -ii.
DE69401837D1 (de) Verfahren zur Herstellung von pyrogenem Siliziumdioxid
HU9301361D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
DE69516438D1 (de) Verfahren zur Herstellung von chlororganischen Silizium-Verbindungen
ATE201025T1 (de) Verfahren zur herstellung von cephalosporinen und zwischenprodukte in diesem verfahren
ATA278988A (de) Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
DE59500930D1 (de) Verfahren zur Herstellung von Ethanolaminen
DE59510180D1 (de) Verfahren zur Herstellung von 4-Amino-2,2,6,6-tetramethyl-piperidin
ATE385232T1 (de) Verfahren zur herstellung von 3, 3', 6, 6'- tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'- tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
DE69505572D1 (de) Verfahren zur Herstellung von Silikasteinen
DE59705601D1 (de) Verfahren zur Herstellung von Siliciumdioxid
DE69218535D1 (de) Verfahren zur Herstellung von kornorientierten Siliziumstahlblechen
ATE132863T1 (de) Verfahren zur herstellung von 6-(substituiertes aminopropionyl)-derivaten von forskolin
DE69915951D1 (de) Verfahren zur Herstellung von Pyrrolidinderivaten
ATE258926T1 (de) Verfahren zur herstellung von ranitidin
DE69501659D1 (de) Verfahren zur Herstellung von gereinigtem Iodwasserstoff
DE69501455D1 (de) Verfahren zur Herstellung von Silizium-Oxy-Karbid
DE69419312D1 (de) Verfahren zur Herstellung von weissem Kohlenstoff
DE69520554D1 (de) Verfahren zur herstellung von indolocarbazol-derivaten
ATE175959T1 (de) Verfahren zur herstellung von azaphenothiazinen
ATE193284T1 (de) Verfahren zur herstellung von benzylsubstituierten rhodaninederivaten
DE69417333D1 (de) Verfahren zur Herstellung von Piperidinderivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US